PuSH - Publikationsserver des Helmholtz Zentrums München

Napieralski, R.* ; Schricker, G.* ; Auer, G.* ; Aubele, M.* ; Perkins, J.* ; Magdolen, V.* ; Ulm, K.* ; Hamann, M.* ; Walch, A.K. ; Weichert, W.* ; Kiehle, M.* ; Weichert, O.G.*

PITX2 DNA-methylation: Predictive versus prognostic value for anthracycline-based chemotherapy in triple-negative breast cancer patients.

Breast Care 16, 523-531 (2021)
Verlagsversion DOI
Free by publisher
Background: PITX2 DNA methylation has been shown to predict outcomes in high-risk breast cancer patients after anthracycline-based chemotherapy. To determine its prognostic versus predictive value, the impact of PITX2 DNA methylation on outcomes was studied in an untreated cohort vs. an anthracycline-treated triple-negative breast cancer (TNBC) cohort. Material and Methods: The percent DNA methylation ratio (PMR) of paired-like homeodomain transcription factor 2 (PITX2) was determined by a validated methylation-specific real-time PCR test. Patient samples of routinely collected archived formalin-fixed paraffin-embedded (FFPE) tissue and clinical data from 144 TNBC patients of 2 independent cohorts (i.e., 66 untreated patients and 78 patients treated with anthracycline-based chemotherapy) were analyzed. Results: The risk of 5- and 10-year overall survival (OS) increased continuously with rising PITX2 DNA methylation in the anthracycline-treated population, but it increased only slightly during 10-year follow-up time in the untreated patient population. PITX2 DNA methylation with a PMR cutoff of 2 did not show significance for poor vs. good outcomes (OS) in the untreated patient cohort (HR = 1.55; p = 0.259). In contrast, the PITX2 PMR cutoff of 2 identified patients with poor (PMR >2) vs. good (PMR ≤2) outcomes (OS) with statistical significance in the anthracycline-treated cohort (HR = 3.96; p = 0.011). The results in the subgroup of patients who did receive anthracyclines only (no taxanes) confirmed this finding (HR = 5.71; p = 0.014). Conclusion: In this hypothesis-generating study PITX2 DNA methylation demonstrated predominantly predictive value in anthracycline treatment in TNBC patients. The risk of poor outcome (OS) correlates with increasing PITX2 DNA methylation.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Anthracyclines ; Biomarker ; Chemotherapy ; Dna Methylation ; Homeodomain Proteins/genetics ; Pitx2 ; Therapy Prediction ; Treatment Outcome ; Triple-negative Breast Cancer/neoplasms ; Tumor/genetics; Adjuvant Chemotherapy; Clinical Validation; Cell; Multicenter; Activation; Biomarker; Pathway; Marker; Risk
ISSN (print) / ISBN 1661-3791
e-ISSN 1661-3805
Zeitschrift Breast Care
Quellenangaben Band: 16, Heft: 5, Seiten: 523-531 Artikelnummer: , Supplement: ,
Verlag Karger
Verlagsort Allschwilerstrasse 10, Ch-4009 Basel, Switzerland
Begutachtungsstatus Peer reviewed
Förderungen Therawis Diagnostics GmbH